Halozyme Therapeutics HALO Net debt / EBITDA
Net debt / EBITDA at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Halozyme Therapeutics’s 10-Q, filed November 3, 2025, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's net debt / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's net debt / EBITDA?
- Halozyme Therapeutics (HALO) reported net debt / EBITDA of 1.5× in Q3 2025.
- How has Halozyme Therapeutics's net debt / EBITDA changed year-over-year?
- Halozyme Therapeutics's net debt / EBITDA decreased by 47.2% year-over-year, from 2.8× to 1.5×.
- What is the long-term trend for Halozyme Therapeutics's net debt / EBITDA?
- Over 4 years (2020 to 2024), Halozyme Therapeutics's net debt / EBITDA has grown at a 10.1% compound annual growth rate (CAGR), from 1.7× to 2.5×.
- What does net debt / EBITDA mean?
- How many years of operating earnings it would take to pay off the company's net debt.
- How do you interpret net debt / EBITDA?
- Lower is safer; lenders often covenant around 3–4×. A negative value means net cash (more cash than debt), a position of strength. Spikes can reflect a temporary EBITDA dip rather than new borrowing.
- How does net debt / EBITDA compare across companies?
- A standard leverage yardstick across non-financial sectors; covenant thresholds vary by industry cash-flow stability.